Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Breast Neoplasms 39Ovarian Neoplasms 29Multiple Myeloma 16Neoplasms 9Recurrence 8Lymphoma 8Fallopian Tube Neoplasms 8Triple Negative Breast Neoplasms 7Lymphoma, Large B-Cell, Diffuse 7Hodgkin Disease 7Carcinoma, Ovarian Epithelial 7Lymphoma, Non-Hodgkin 6Sarcoma 5Neoplasm Metastasis 5Burkitt Lymphoma 3Uterine Cervical Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Mesothelioma, Malignant 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lung Neoplasms 2Liver Neoplasms 2Leukemia 2Leiomyosarcoma 2Kidney Neoplasms 2Endometrial Neoplasms 2Disease Progression 2Vulvar Neoplasms 1Vaginal Neoplasms 1

Interventions

Cyclophosphamide 53fludarabine phosphate 50Tacrolimus 41Busulfan 41Peripheral Blood Stem Cell Transplantation 37Mycophenolic Acid 36Whole-Body Irradiation 34Antilymphocyte Serum 34Cyclosporine 27Methotrexate 25fludarabine 24Melphalan 20Radiotherapy 19Filgrastim 16Methylprednisolone 14Cord Blood Stem Cell Transplantation 12Cytarabine 11thymoglobulin 10ruxolitinib 10Specimen Handling 10Biopsy 10Cyclosporins 9sargramostim 8Sirolimus 8Etoposide 8Alemtuzumab 8Thiotepa 7Stem Cell Transplantation 7Granulocyte Colony-Stimulating Factor 7Azacitidine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Myeloproliferative Disorders × liposomal doxorubicin × Clear all
NCT00074490 2018-12-31

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
442 enrolled 17 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡